Somnomed (ASX: SOM) – sleeping breathing disorder treatment

 

COMPANY SCOREBOARD

Pro PlusProCon PlusCon
  • Marketing leading technology
  • Directors support and skin in the game
  • Close to cash flow breakeven
  • High interest rate loan
 

ABOUT COMPANY

SomnoMed (SOM) (http://somnomed.com/au/) is the global leader in COAT (Continuous Open Airway Therapy) and provides clinically proven diagnostic and treatment options for sleep-related breathing disorders such as obstructive sleep apnea (OSA) and sleep bruxism. Founded in Australia in 2004, it is trading in over 26 countries worldwide.

CAPITAL STRUCTURE

The directors have been actively buying on market for both 2020 and 2021, they also had large amount of 15c options conversion, so their average purchase price would be between 80c and $1.

The company has a $16m loan with an interest rate of BBSW+9%.

BUSINESS

Below is the company’s five year financial performance

SUMMARY

The company targets EBITDA to be 10% of total revenue by FY27. However, even it was the case today, the company still makes the accounting loss.